FDA批准Verquvo治疗心力衰竭

2021-01-24 Allan MedSci原创

美国食品药品监督管理局(FDA)已批准MSD的Verquvo(vericiguat),用于治疗有症状的慢性心力衰竭且射血分数低于45%的成年患者。

心力衰竭是一个严重的全球性公众健康问题,是大部分血管疾病发展的最终阶段。发病率高,危害性大,预后不良。目前全世界有超过2600万人患有心衰,在中国,心衰的患病率为0.9%,估计有400-500万心衰患者。随着年龄的增高,心衰的患病率显著上升。

美国食品药品监督管理局(FDA)已批准MSD的Verquvo(vericiguat),用于治疗有症状的慢性心力衰竭且射血分数低于45%的成年患者。Verquvo(vericiguat)先前已被批准用于降低心血管死亡和心力衰竭住院的风险。

这项批准是基于VICTORIA III期试验的结果,Verquvo达到了主要终点。在研究期间,研究人员观察到,与安慰剂相比,Verquvo(vericiguat)将心血管死亡或心力衰竭住院的年绝对风险降低了4.2%。

MSD首席医学官Roy Baynes说:“Verquvo已被证明可以降低因心力衰竭住院或需要门诊静脉利尿剂而导致的心血管死亡和心力衰竭住院风险。我们很高兴为有症状的慢性心力衰竭患者提供有意义的新治疗选择”。

 

原始出处:

http://www.pharmatimes.com/news/us_approval_for_msds_heart_failure_med_verquvo_1361684

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1839908, encodeId=6da81839908a4, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Thu Mar 04 23:55:47 CST 2021, time=2021-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922583, encodeId=04f092258385, content=很好很好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8585442638, createdName=Aidy, createdTime=Wed Feb 03 22:37:55 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921022, encodeId=b6c19210223d, content=好事, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/11/07/32f6eeca95f16df602e2fe81e7416090.jpg, createdBy=ddb32421444, createdName=精气神, createdTime=Fri Jan 29 13:42:38 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919913, encodeId=492f9199136f, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210125/f2ea4b3022754436821f6c8095626684/2e4d97284fcc438080fb0be3805c0e0e.jpg, createdBy=fe4f5454301, createdName=申流沙, createdTime=Tue Jan 26 07:08:26 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919499, encodeId=786d919499a6, content=通俗易懂, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8bd5455325, createdName=ms2000000770930337, createdTime=Sun Jan 24 18:13:17 CST 2021, time=2021-01-24, status=1, ipAttribution=)]
    2021-03-04 bugit
  2. [GetPortalCommentsPageByObjectIdResponse(id=1839908, encodeId=6da81839908a4, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Thu Mar 04 23:55:47 CST 2021, time=2021-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922583, encodeId=04f092258385, content=很好很好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8585442638, createdName=Aidy, createdTime=Wed Feb 03 22:37:55 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921022, encodeId=b6c19210223d, content=好事, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/11/07/32f6eeca95f16df602e2fe81e7416090.jpg, createdBy=ddb32421444, createdName=精气神, createdTime=Fri Jan 29 13:42:38 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919913, encodeId=492f9199136f, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210125/f2ea4b3022754436821f6c8095626684/2e4d97284fcc438080fb0be3805c0e0e.jpg, createdBy=fe4f5454301, createdName=申流沙, createdTime=Tue Jan 26 07:08:26 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919499, encodeId=786d919499a6, content=通俗易懂, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8bd5455325, createdName=ms2000000770930337, createdTime=Sun Jan 24 18:13:17 CST 2021, time=2021-01-24, status=1, ipAttribution=)]
    2021-02-03 Aidy

    很好很好!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1839908, encodeId=6da81839908a4, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Thu Mar 04 23:55:47 CST 2021, time=2021-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922583, encodeId=04f092258385, content=很好很好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8585442638, createdName=Aidy, createdTime=Wed Feb 03 22:37:55 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921022, encodeId=b6c19210223d, content=好事, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/11/07/32f6eeca95f16df602e2fe81e7416090.jpg, createdBy=ddb32421444, createdName=精气神, createdTime=Fri Jan 29 13:42:38 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919913, encodeId=492f9199136f, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210125/f2ea4b3022754436821f6c8095626684/2e4d97284fcc438080fb0be3805c0e0e.jpg, createdBy=fe4f5454301, createdName=申流沙, createdTime=Tue Jan 26 07:08:26 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919499, encodeId=786d919499a6, content=通俗易懂, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8bd5455325, createdName=ms2000000770930337, createdTime=Sun Jan 24 18:13:17 CST 2021, time=2021-01-24, status=1, ipAttribution=)]
    2021-01-29 精气神

    好事

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1839908, encodeId=6da81839908a4, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Thu Mar 04 23:55:47 CST 2021, time=2021-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922583, encodeId=04f092258385, content=很好很好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8585442638, createdName=Aidy, createdTime=Wed Feb 03 22:37:55 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921022, encodeId=b6c19210223d, content=好事, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/11/07/32f6eeca95f16df602e2fe81e7416090.jpg, createdBy=ddb32421444, createdName=精气神, createdTime=Fri Jan 29 13:42:38 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919913, encodeId=492f9199136f, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210125/f2ea4b3022754436821f6c8095626684/2e4d97284fcc438080fb0be3805c0e0e.jpg, createdBy=fe4f5454301, createdName=申流沙, createdTime=Tue Jan 26 07:08:26 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919499, encodeId=786d919499a6, content=通俗易懂, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8bd5455325, createdName=ms2000000770930337, createdTime=Sun Jan 24 18:13:17 CST 2021, time=2021-01-24, status=1, ipAttribution=)]
    2021-01-26 申流沙

    好文章

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1839908, encodeId=6da81839908a4, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Thu Mar 04 23:55:47 CST 2021, time=2021-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922583, encodeId=04f092258385, content=很好很好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8585442638, createdName=Aidy, createdTime=Wed Feb 03 22:37:55 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921022, encodeId=b6c19210223d, content=好事, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/11/07/32f6eeca95f16df602e2fe81e7416090.jpg, createdBy=ddb32421444, createdName=精气神, createdTime=Fri Jan 29 13:42:38 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919913, encodeId=492f9199136f, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210125/f2ea4b3022754436821f6c8095626684/2e4d97284fcc438080fb0be3805c0e0e.jpg, createdBy=fe4f5454301, createdName=申流沙, createdTime=Tue Jan 26 07:08:26 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919499, encodeId=786d919499a6, content=通俗易懂, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8bd5455325, createdName=ms2000000770930337, createdTime=Sun Jan 24 18:13:17 CST 2021, time=2021-01-24, status=1, ipAttribution=)]
    2021-01-24 ms2000000770930337

    通俗易懂

    0

相关资讯

深度盘点:2020年FDA批准53款新药上市,肿瘤药占1/3

2020年的上半年,美国FDA的药物评估与研究中心(CEDR)已经批准了

FDA授予Ilixadencel治疗肝细胞癌(HCC)的“孤儿药称号”

制药公司Immunicum近日宣布,美国食品药品监督管理局(FDA)已经授予Ilixadencel治疗肝细胞癌(HCC)的“孤儿药称号”(ODD)。

​阿斯利康达格列净治疗慢性肾病适应症获FDA优先审评资格

1月6日,阿斯利康SGLT2(钠-葡萄糖协同转运蛋白2)抑制剂达格列净上市申请获FDA优先审评资格,用于治疗成人新确诊或恶化的慢性肾病(CKD),无论这些患者是否患有2型糖尿病(T2D)。达格列净有可

合成生物药物可利霉素(Carrimycin)治疗COVID-19:FDA已允许开展III期临床试验

Carrimycin已成为世界上第一款用于重症COVID-19患者的合成生物药物,美国食品药品监督管理局(FDA)已允许开展Carrimycin治疗COVID-19的III期临床试验。

美国FDA批准阿斯利康和第一三共制药的Enhertu用于胃腺癌

FDA近日表示,已扩大阿斯利康和第一三共的Enhertu(fam-trastuzumab deruxtecan-nxki)的适应症范围。

FDA授予Zenocutuzumab治疗NRG1基因融合肿瘤的“快速通道资格”

肿瘤学公司Merus今天宣布,美国食品药品监督管理局(FDA)已授予Zenocutuzumab(Zeno)治疗具有NRG1基因融合的转移性实体瘤患者的“快速通道资格”。

拓展阅读

JAHA:心力衰竭患者虚弱与代谢易感性的关系

在这个心衰队列中,虚弱和MVX呈弱相关。两者都独立地有助于死亡风险的分层,表明它们代表了心衰的不同易感性。

Genes & Diseases:耿庆山/刘惊今教授团队揭示运动改善心力衰竭的潜在机制

从人群研究、动物模型和细胞水平研究Metrnl改善心衰的效果及分子机制。从骨骼肌分泌到改善心衰多器官互作的新角度研究潜在机制,为临床心衰防治提供新治疗策略,为运动康复治疗心衰提供新依据。

JAMA Netw Open:心力衰竭患者的经济负担、死亡率和健康状况

急性失代偿性心力衰竭患者中感知的经济负担与更高的死亡风险和较差的健康状况相关,但与心力衰竭再住院风险无关,这表明感知的经济负担可能是评估风险和潜在干预的方便工具。

王华楠教授/刘佳副研究员《Biomaterials》: 局部递送具有蛋白/多酚自组装保护层的干细胞球治疗心肌梗死

这项研究为设计功能性生物材料增强干细胞免疫调节治疗MI开辟新的途径。

JAHA:心理治疗对心力衰竭和缺血性心脏病患者预后的影响

针对焦虑或抑郁的心理健康治疗对心血管疾病患者的预后有显著影响,包括减少住院、急诊就诊,并在某些情况下提高生存率。

Drug Des Devel Ther:芪附益心方通过增强β-Arrestin2介导的SERCA2a SUMOylation改善心力衰竭

阐明中药芪附益心方(QFYXF)通过促进β-arrestin2 (β-arr2)介导的SERCA2a SUMOylation改善心衰的保护机制。